Medley Pharmaceuticals Limited

Medley Pharmaceuticals Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN U24230MH1975PLC018296 Incorporated 15 April 1975 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Public Limited Company pharma
Data last updated
Revenue · FY 2025
₹1,114.92 Cr
▲ 8% YoY
Net profit · FY 2025
₹247.97 Cr
Net margin 22.2%
EBITDA · FY 2025
₹356.19 Cr
EBITDA margin 31.9%
Authorised capital
₹33 Cr
Registered with MCA
Paid-up capital
₹30.06 Cr
Issued & subscribed
Open charges
₹57.4 Cr
Satisfied ₹254.55 Cr
Company age
51 yrs
Est. 1975
Employees · EPFO
2,852
Provident fund records

About Medley Pharmaceuticals Limited

Data last updated:

Medley Pharmaceuticals Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 15 April 1975 and has been in existence for over 51 years.

Its director Sahir Khatib is #1,608 among India's richest people (2026). Its director Suhel Khatib is #1,608 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24230MH1975PLC018296. Its GSTIN is 27AAACM2764J1ZC (Maharashtra). The company holds 27 GST registrations, of which 23 are active.

The company has an authorised share capital of ₹33 Cr and a paid-up capital of ₹30.06 Cr. It was formerly known as Medley Pharmaceuticals Private Limited. It is led by directors including Sahir Sami Khatib (Managing Director) and Saba Mir Asif Ali (Whole-Time Director).

Its last annual general meeting (AGM) was held on 17 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Medley Housed 2 M I D C Area Andheri (East), Mumbai, Maharashtra, India – 400093.

As per the financials filed for FY 2025, the company reported a revenue of ₹1,114.92 Cr, a growth of 8% compared to the previous year. For the same year it recorded a net profit of ₹247.97 Cr (net margin 22.2%) and EBITDA of ₹356.19 Cr (EBITDA margin 31.9%). Revenue has grown at a compounded annual rate (CAGR) of 7% over three years and 9% over five years.

The company has about 2,852 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: Medley Pharmaceuticals. As per MCA filings, the company has open charges of ₹57.4 Cr and satisfied charges of ₹254.55 Cr on record. Court records list 290 cases involving the company, including 191 filed by the company and 99 filed against it; 76 cases are pending. The company has 9 deals on record (7 secondary share transfers, 2 funding rounds), with disclosed funding of ₹4.2 Cr; the latest was in September 2021. Its 10 peer companies in the Pharma industry (Formulations, Pharmaceuticals) are compared by revenue, 5 larger and 5 smaller; the largest is Corona Remedies Limited with revenue of ₹1,202.35 Cr. The company has 15 MSME Form 1 returns on record between 2018 and 2024, listing 252 overdue payments to 76 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website medleylab.com.

Company Details of Medley Pharmaceuticals Limited
CIN U24230MH1975PLC018296
Registration Number 018296
Incorporation Date 15 April 1975
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 17 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant

CIN History of Medley Pharmaceuticals Limited

Medley Pharmaceuticals has one previous CIN (Corporate Identification Number): U24230MH1975PTC018296. The current CIN is U24230MH1975PLC018296, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U24230MH1975PLC018296Current
U24230MH1975PTC018296Previous
Key People
Sahir Sami Khatib Managing Director Saba Mir Asif Ali Whole-Time Director Sarosh Sami Khatib Whole-Time Director

Recognitions & Rankings of Medley Pharmaceuticals

Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    medleylab.com
  • Social Media
    Locked
  • Registered Address
    Medley Housed 2 M I D C Area Andheri (East), Mumbai, Maharashtra, India – 400093
  • Industry
    Pharma, Drug Formulation & Development
Comprehensive company report
Medley Pharmaceuticals Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full Medley Pharmaceuticals Limited report

Financials, compliance, directors, charges, ownership and filings for Medley Pharmaceuticals Limited in one report.

Financials from 2015 Directors & ownership Charges & compliance

Associated Brands with Medley Pharmaceuticals Limited

Medley Pharmaceuticals operates one associated brand: Medley Pharmaceuticals. Each brand links to its own profile.

BrandDescriptionWebsite
Medley Pharmaceuticals
Over-the-counter drugs, APIs, and other pharmaceuticals are manufactured by Medley.medleylab.com

Business Activity of Medley Pharmaceuticals Limited

The main business activity of Medley Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical productsLocked
Premium access

Business activity turnover details

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Financials of Medley Pharmaceuticals Limited FY 2025 filings available

Medley Pharmaceuticals Limited reported revenue of ₹1,114.92 Cr (up 8% YoY) for FY 2025.

Revenue · FY 2025
₹1,114.92 Cr ▲ 8%
Net profit · FY 2025
₹247.97 Cr margin 22.2%
EBITDA · FY 2025
₹356.19 Cr margin 31.9%

Compounded Annual Growth Rate (CAGR) of Medley Pharmaceuticals Limited

Revenue CAGR growth
1 year
▲ 8%
3 years · compounded
▲ 7%
5 years · compounded
▲ 9%
EBITDA CAGR growth
1 year
▲ 34%
3 years · compounded
▲ 24%
5 years · compounded
▲ 22%

Revenue has grown at a compounded annual rate (CAGR) of 9% over five years, including 8% growth in the latest year. EBITDA rose 34% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary of Medley Pharmaceuticals Limited

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profit and Loss Statement
Revenue from Operations••••••••••••••••••••
Other Income••••••••••••••••••••
Total Revenue••••••••••••••••••••
Cost of Materials Consumed••••••••••••••••••••
Employee Benefit Expense••••••••••••••••••••
Finance Costs••••••••••••••••••••
Depreciation and Amortisation••••••••••••••••••••
Other Expenses••••••••••••••••••••
Total Expenses••••••••••••••••••••
EBITDA₹356.19 Cr••••••••••••••••
Profit Before Tax••••••••••••••••••••
Tax Expense••••••••••••••••••••
Net Profit (PAT)₹247.97 Cr••••••••••••••••
Balance Sheet
Share Capital••••••••••••••••••••
Reserves and Surplus••••••••••••••••••••
Net Worth (Total Equity)••••••••••••••••••••
Long-term Borrowings••••••••••••••••••••
Short-term Borrowings••••••••••••••••••••
Trade Payables••••••••••••••••••••
Total Liabilities••••••••••••••••••••
Fixed Assets••••••••••••••••••••
Investments••••••••••••••••••••
Inventories••••••••••••••••••••
Trade Receivables••••••••••••••••••••
Cash and Bank Balance••••••••••••••••••••
Total Assets••••••••••••••••••••

Financial Ratios of Medley Pharmaceuticals Limited

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
EBITDA Margin31.9%••••••••••••••••
Net Profit Margin22.2%••••••••••••••••
Return on Equity (ROE)••••••••••••••••••••
Return on Capital Employed (ROCE)••••••••••••••••••••
Return on Assets (ROA)••••••••••••••••••••
Liquidity and Debt
Current Ratio••••••••••••••••••••
Quick Ratio••••••••••••••••••••
Debt-to-Equity Ratio••••••••••••••••••••
Interest Coverage Ratio••••••••••••••••••••
Efficiency and Growth
Asset Turnover••••••••••••••••••••
Receivable Days••••••••••••••••••••
Payable Days••••••••••••••••••••
Inventory Days••••••••••••••••••••
Revenue Growth••••••••••••••••••••
Net Profit Growth••••••••••••••••••••

Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Medley Pharmaceuticals are in the company report.

Premium access

Financial statements from 2015

Earlier years and trend charts are in the company report.

  • Income statements
  • Balance sheets
  • Cash-flow statements
  • Ratios and benchmarks

Verified entity values are shown only after access is granted.

Board of Directors and KMP of Medley Pharmaceuticals Limited

Medley Pharmaceuticals Limited currently reports 7 directors and 1 key managerial person. 19 former directors have served the organization.

Current Directors and KMP
NameDesignationAppointment DateTenureStatus
Ravindra Baliram MoreCompany Secretary01 Dec 201411 Years 10 MonthsCurrent
Sahir Sami Khatib
Also directs: Blue-Fin Frozen Foods Private Limited, Sinkhai Leathers Private Limited, Sorbo Monni Chemicals Private Limited and 5 more
Managing Director01 Apr 201511 Years 6 MonthsCurrent
Mohamed Aslam Abdul Rahman Sheikh
Also directs: Channels Medical Systems Private Limited
Director28 Jun 20242 Years 3 MonthsCurrent
Saba Mir Asif AliWhole-Time Director24 Feb 201511 Years 7 MonthsCurrent
Suhel Sami Khatib
Also directs: Sorbo Monni Chemicals Private Limited, Minar Chemicals Pvt Ltd
Director01 Apr 201016 Years 6 MonthsCurrent
Sarosh Sami Khatib
Also directs: Sinkhai Leathers Private Limited, Sinkhai Healthcare Limited, Steranco Healthcare Private Limited
Whole-Time Director17 Jul 198739 Years 3 MonthsCurrent
Showing 6 of 8 current directors and KMP. View all directors and KMP

Peer Comparison of Medley Pharmaceuticals Limited

Medley Pharmaceuticals Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Corona Remedies Limited₹1,202.35 Cr (FY 2025)••••••••18.0%••••Ahmedabad, Gujarat, India
Hetero Healthcare Limited₹1,189.8 Cr (FY 2025)••••••••16.0%••••Hyderabad, Telangana, India
BDR Pharmaceuticals International Private Limited₹1,137.31 Cr (FY 2025)••••••••2.0%••••Mumbai, Maharashtra, India
Tirupati Medicare Limited₹1,119.15 Cr (FY 2025)••••••••6.0%••••New Delhi, Delhi, India
Zuventus Healthcare Limited₹1,117.95 Cr (FY 2025)••••••••4.0%••••Pune, Maharashtra, India
Medley Pharmaceuticals Limited this company₹1,114.92 Cr (FY 2025)••••••••8.0%••••Mumbai, Maharashtra, India
Troikaa Pharmaceuticals Limited₹1,088.44 Cr (FY 2025)••••••••12.0%••••Ahmedabad, Gujarat, India
Tenshi Pharmaceuticals Private Limited₹1,071.06 Cr (FY 2024)••••••••98.0%••••Bangalore, Karnataka, India
Centaur Pharmaceuticals Private Limited₹1,060.17 Cr (FY 2025)••••••••22.0%••••Mumbai, Maharashtra, India
Boehringer Ingelheim India Private Limited₹1,049.1 Cr (FY 2025)••••••••3.0%••••Mumbai, Maharashtra, India
Blue Cross Laboratories Private Limited₹1,021.41 Cr (FY 2025)••••••••5.0%••••Mumbai, Maharashtra, India

Peers are the five companies nearest above and the five nearest below Medley Pharmaceuticals by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.

Auditor Details of Medley Pharmaceuticals Limited

Medley Pharmaceuticals Limited is audited by S R B C & CO LLP for the financial year 2024.

NameStatusAppointment DateCessation Date
S R B C & CO LLPLockedLockedLocked
Premium access

Complete auditor history

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Ownership and Shareholding of Medley Pharmaceuticals Limited

Premium access

Shareholding and ownership data

Promoter, institutional, public and beneficial ownership figures are in the company report.

  • Ownership categories
  • Historical changes
  • Group structure
  • FII and DII holdings

Verified entity values are shown only after access is granted.

Charges & Borrowings of Medley Pharmaceuticals Limited

Open charges
₹57.4 Cr
Satisfied charges
₹254.55 Cr
Breakdown by lending institutions
Others₹40.10 Cr
State Bank of India₹17.30 Cr
Latest charge details
DateLenderAmountStatus
02 Dec 2025Others₹20 CrOpen
17 Jun 2022Others₹20 CrOpen
15 Apr 2021Others₹10 LakhOpen
31 Mar 1999State Bank of India₹17.3 CrOpen
30 Mar 2015Icici Bank Limited₹6.5 CrSatisfied

Total charge records: 27 View all charges

Deals & Funding of Medley Pharmaceuticals Limited

Medley Pharmaceuticals Limited has 9 deals on record (7 secondary share transfers, 2 funding rounds), with disclosed funding of ₹4.2 Cr; the latest was in September 2021.

Total deals
9
Secondary share transfers
7
Funding rounds
2
Disclosed funding
₹4.2 Cr

Deals on record (5 of 9)

WhenDealAmountParties
Sep 2021Secondary share transferUndisclosedBuyer: 4 individuals
Seller: 2 individuals
Sep 2020Secondary share transferUndisclosedSeller: 4 individuals
Aug 2020Secondary share transferUndisclosedBuyer: an individual
Seller: an individual
Oct 2018Secondary share transferUndisclosedBuyer: 4 individuals
Seller: 4 individuals
Nov 2006Funding round₹4 CrInvestors: Medley Laboratories Private Limited , 3 individuals
Premium access

Full deal history

All 9 deals with amounts, valuations, instruments and every party are in the company report.

  • Every funding round and share transfer
  • Amounts and valuations
  • Investors, buyers and sellers
  • Instruments and deal dates

Verified entity values are shown only after access is granted.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME Payment Delays by Medley Pharmaceuticals Limited

Medley Pharmaceuticals Limited has 15 MSME Form 1 returns on record between 2018 and 2024, listing 252 overdue payments to 76 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 76)

SupplierAmount dueDue sinceReported on
Accurate Research & Analytical Private Limited••••••••••••
Maple Biotech Pvt Ltd••••••••••••
Kaulchand H. Jogani & Suresh K••••••••••••
an individual supplier••••••••••••
an individual supplier••••••••••••
Premium access

Full MSME payment history

Every supplier, amount and due date from all 15 MSME Form 1 returns is in the company report.

  • Every reported supplier due
  • Amounts and due dates
  • Reasons given in each return
  • Period-by-period history

Verified entity values are shown only after access is granted.

Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.

Employees and EPFO Compliance at Medley Pharmaceuticals Limited

Medley Pharmaceuticals Limited has a workforce of 2,852 employees as of Feb 27, 2025.

Employee count
2,852
Active EPFO establishments
2
Employee growth
-0.42%
Premium access

Employee and EPFO history

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

Group Structure of Medley Pharmaceuticals Limited

Medley Pharmaceuticals has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key Subsidiaries
Company NameCINShares Held
Sinkhai Healthcare LimitedU24230MH2005PLC151938Locked

Showing major subsidiaries. Total: 1.

Recent Activity on Medley Pharmaceuticals Limited

Medley Pharmaceuticals Limited has 25 board changes on record since 1987: 8 appointments and 17 cessations. The latest: Mohamed Aslam Abdul Rahman Sheikh ceased to be Additional Director on 29 Sep 2024.

Charges
A charge with Others amounted to Rs. 20.00 Cr with Charge ID 101198123 was registered on 02 Dec 2025.
AGM
Medley Pharmaceuticals Limited last Annual general meeting of members was held on 17 Sep 2025 as per latest MCA records.
Filing
Medley Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Ceased
Mohamed Aslam Abdul Rahman Sheikh ceased to be Additional Director.
Ceased
Sucheta Mudgerikar ceased to be Additional Director.
Appointed
Sucheta Mudgerikar was appointed as Director.
Charges
A charge with Others of Rs. 20.00 Cr registered on 17 Jun 2022 with Charge ID 100589116 was modified on 08 Jul 2024.
Appointed
Mohamed Aslam Abdul Rahman Sheikh was appointed as Director.
Charges
A charge registered on 20 May 2009 via Charge ID 10165956 with Others was fully satisfied on 18 May 2023.
Ceased
Firdaus Jehangir Tarachand ceased to be CFO.
Charges
A charge with Others amounted to Rs. 20.00 Cr with Charge ID 100589116 was registered on 17 Jun 2022.
Charges
A charge with Others amounted to Rs. 0.10 Cr with Charge ID 100444522 was registered on 15 Apr 2021.

78 earlier events are listed in the company report.

Credit Ratings, Litigation & Regulatory Alerts for Medley Pharmaceuticals Limited

Premium access

Credit ratings, litigation, and regulatory alerts

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Medley Pharmaceuticals Limited

Premium access

Corporate group structure

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

GST Compliance of Medley Pharmaceuticals Limited

Medley Pharmaceuticals has 27 GST registrations: 23 active and 4 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
27
Active
23
Cancelled / inactive
4
GSTINStateStatusRegistered on
27AAACM2764J1ZCMaharashtraActive01 Jul 2017
27AAACM2764J2ZBMaharashtraActive16 Jul 2017
03AAACM2764J1ZMPunjabActive01 Jul 2017
05AAACM2764J1ZIUttarakhandActive01 Jul 2017
Premium access

GST registrations and filing compliance

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Medley Pharmaceuticals Limited

Premium access

MCA filings and documents

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Related news about Medley Pharmaceuticals Limited

Sierra, MCC and Medley to merge
29 Jul 2019 · PE Hub

Frequently Asked Questions about Medley Pharmaceuticals Limited

Medley Pharmaceuticals is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 15 April 1975 (51+ years old) and is registered under CIN U24230MH1975PLC018296.

Medley Pharmaceuticals reported revenue of ₹1,114.92 Cr for FY 2025 (up 8% YoY).

Medley Pharmaceuticals has 8 current directors and KMP:

Medley Pharmaceuticals reported a net profit of ₹247.97 Cr (net margin 22.2%) and EBITDA of ₹356.19 Cr (EBITDA margin 31.9%) for FY 2025, as per its filed financial statements.

The compounded annual growth rate (CAGR) of the revenue of Medley Pharmaceuticals is 7% over three years and 9% over five years. In the latest year (FY 2025) revenue rose 8%. CAGR is the steady yearly rate that links the first and the last year.

The GSTIN of Medley Pharmaceuticals is 27AAACM2764J1ZC, registered in Maharashtra. The company has 27 GST registrations in all, of which 23 are active and 4 are cancelled or inactive. Other active GSTINs include 27AAACM2764J2ZB (Maharashtra), 03AAACM2764J1ZM (Punjab), 05AAACM2764J1ZI (Uttarakhand).

The CIN (Corporate Identification Number) of Medley Pharmaceuticals is U24230MH1975PLC018296. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Medley Pharmaceuticals has 290 court cases on record: 191 filed by the company and 99 filed against it. 76 are pending. Most are in the high courts.

Medley Pharmaceuticals was incorporated on 15 April 1975, making it 51+ years old. It is registered with the Registrar of Companies, Mumbai.

Medley Pharmaceuticals has 9 deals on record (7 secondary share transfers, 2 funding rounds), with disclosed funding of ₹4.2 Cr; the latest was in September 2021.

The peers of Medley Pharmaceuticals by revenue are Corona Remedies Limited, Hetero Healthcare Limited, BDR Pharmaceuticals International Private Limited, Tirupati Medicare Limited, Zuventus Healthcare Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).

Mohamed Aslam Abdul Rahman Sheikh ceased to be Additional Director on 29 Sep 2024. Sucheta Mudgerikar ceased to be Additional Director on 29 Sep 2024. Sucheta Mudgerikar was appointed as Director on 25 Jul 2024. Medley Pharmaceuticals has 25 board changes on record in total.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available